https://scholars.lib.ntu.edu.tw/handle/123456789/634976| Title: | Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study | Authors: | Chiu, Chao-Hua Lin, Meng-Chih Wei, Yu-Feng Chang, Gee-Chen Su, Wu-Chou Hsia, Te-Chun Su, Jian Wang, Anne Kuei-Fang Jen, Min-Hua Puri, Tarun JIN-YUAN SHIH |
Issue Date: | Jul-2023 | Journal Volume: | 18 | Journal Issue: | 4 | Source: | Targeted oncology | Abstract: | In RELAY, a randomized, double-blind, phase III trial investigating the efficacy and safety of ramucirumab+erlotinib (RAM+ERL) or ERL+placebo (PBO) in patients with untreated, stage IV, epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), RAM+ERL demonstrated superior progression-free survival (PFS) versus PBO+ERL, with no new safety signals. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634976 | ISSN: | 17762596 | DOI: | 10.1007/s11523-023-00975-5 |
| Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
